BAX

Baxter International Inc. [BAX] Stock Forecast

Q: What is Baxter International Inc. stock symbol ?

Baxter International Inc. is a US stock, located in Deerfield of Il and trading under the symbol BAX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BAX Stock Summary

EPS has increased from the previous year and become positive (Yearly statements)

Earnings are expected to fall -100% next year

BAX has less than 1 year of cash runway

Debt-to-Equity ratio of 1.71 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

BAX

Top 10 Correlated Stocks

BAX

In the News

BAX Financial details

Company Rating

Strong Buy

Market Cap

20.49B

Income

2.66B

Revenue

14.95B

Book val./share

16.57

Cash/share

6.3

Dividend

1.16

Dividend %

2.72%

Employees

60K

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

8.14

Forward P/E

PEG

-0.9

P/S

1.45

P/B

2.57

P/C

6.27

P/FCF

20.94

Quick Ratio

0.91

Current Ratio

1.48

Debt / Equity

1.71

LT Debt / Equity

1.37

EPS (TTM)

-0.44

EPS next Y

EPS next Q

EPS this Y

-90.63%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

5.45%

Revenue Q/Q

4.77%

EPS Q/Q

-166.67%

SMA20

-4.76%

SMA50

2.56%

SMA100

11.11%

Inst Own

66.69%

Inst Trans

0.78%

ROA

ROE

38%

ROC

0.01%

Gross Margin

34%

Oper. Margin

Profit Margin

18%

Payout

22%

Shs Outstand

Shs Float

Target Price

52W Range

31.01-50.21

52W High

-21%

52W Low

+27.42%

RSI

Rel Volume

0.47

Avg Volume

3.62M

Volume

1.7M

Perf Week

-6.22%

Perf Month

-9.76%

Perf Quarter

22.82%

Perf Half Y

24.06%

Beta

0.634

Volatility

0.29%, 1.24%

Prev Close

-0.38%

Price

39.5

Change

-0.6%

BAX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	22.32	22.93	25.47	29.99	29.27
Net income per share	1.97	2.17	2.56	-4.8	5.25
Operating cash flow per share	4.13	3.67	4.43	2.4	3.41
Free cash flow per share	2.77	2.28	2.95	1.06	2.04
Cash per share	6.55	7.33	5.88	3.41	6.32
Book value per share	15.49	17.07	18.08	11.57	16.6
Tangible book value per share	6.7	7.54	-16.95	-15.36	-8.15
Share holders equity per share	15.49	17.07	18.08	11.57	16.6
Interest debt per share	11.93	13.63	36.86	34.94	28.4
Market cap	42.56B	40.84B	43.09B	25.69B	19.56B
Enterprise value	45.19B	43.92B	58.45B	41.18B	30.73B
P/E ratio	42.52	37.06	33.56	-10.61	7.37
Price to sales ratio	3.75	3.5	3.37	1.7	1.32
POCF ratio	20.23	21.86	19.39	21.21	11.33
PFCF ratio	30.23	35.24	29.14	48.29	18.92
P/B Ratio	5.4	4.7	4.75	4.4	2.33
PTB ratio	5.4	4.7	4.75	4.4	2.33
EV to sales	3.98	3.76	4.57	2.73	2.07
Enterprise value over EBITDA	25.6	30.8	35.02	48.22	17.55
EV to operating cash flow	21.48	23.51	26.31	34.01	17.8
EV to free cash flow	32.09	37.89	39.52	77.41	29.72
Earnings yield	0.02	0.03	0.03	-0.09	0.14
Free cash flow yield	0.03	0.03	0.03	0.02	0.05
Debt to equity	0.76	0.78	2.02	2.95	1.65
Debt to assets	0.33	0.34	0.55	0.61	0.49
Net debt to EBITDA	1.49	2.16	9.2	18.14	6.38
Current ratio	2.32	2.52	2.09	1.69	1.48
Interest coverage	8.79	4.5	4.06	-1.39	0.76
Income quality	2.08	1.68	1.72	-0.5	-25.01
Dividend Yield	0.01	0.01	0.01	0.02	0.03
Payout ratio	0.42	0.43	0.41	-0.24	0.22
Sales general and administrative to revenue	0.29	0.21	0.23	0.26	0.26
Research and developement to revenue	0.05	0.04	0.04	0.04	0.05
Intangibles to total assets	0.25	0.24	0.53	0.48	0.45
Capex to operating cash flow	-0.33	-0.38	-0.33	-0.56	-0.4
Capex to revenue	-0.06	-0.06	-0.06	-0.04	-0.05
Capex to depreciation	-0.88	-0.86	-0.83	-0.48	-0.55
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	26.18	28.84	32.26	35.37	44.28
ROIC	0.07	0.03	0.02	-0.02	0.01
Return on tangible assets	0.07	0.07	0.08	-0.17	0.17
Graham Net	-9.23	-9.92	-36.23	-34.23	-25.97
Working capital	4.27B	5.08B	4.64B	3.27B	3.1B
Tangible asset value	3.41B	3.84B	-8.51B	-7.74B	-4.13B
Net current asset value	-2.78B	-2.88B	-15.53B	-14.38B	-10.21B
Invested capital	0.76	0.78	2.02	2.95	1.65
Average receivables	1.85B	1.99B	2.4B	2.73B	2.75B
Average payables	948M	967.5M	1.14B	1.19B	1.19B
Average inventory	1.65B	1.78B	2.18B	2.59B	2.77B
Days sales outstanding	60.91	64.95	77.46	66.46	67.59
Days payables outstanding	49.32	53.72	59.23	42.79	46.04
Days of inventory on hand	91.4	98.69	116.6	102.11	104.77
Receivables turnover	5.99	5.62	4.71	5.49	5.4
Payables turnover	7.4	6.79	6.16	8.53	7.93
Inventory turnover	3.99	3.7	3.13	3.57	3.48
ROE	0.13	0.13	0.14	-0.42	0.32
Capex per share	-1.37	-1.39	-1.48	-1.35	-1.37

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	7.71	7.23	7.33	7.31	7.66
Net income per share	0.36	0.09	-0.28	4.95	0.48
Operating cash flow per share	0.87	0.95	0.69	0.72	1.05
Free cash flow per share	0.47	0.61	0.39	0.38	0.67
Cash per share	3.41	3.31	3.4	11.42	6.3
Book value per share	11.57	11.64	11.01	15.98	16.57
Tangible book value per share	-15.36	-14.98	-14.34	-8.82	-8.14
Share holders equity per share	11.57	11.64	11.01	15.98	16.57
Interest debt per share	34.38	33.68	33.7	33.64	28.56
Market cap	25.69B	20.48B	23.05B	19.13B	19.6B
Enterprise value	41.18B	35.7B	38.25B	30.28B	30.77B
P/E ratio	35.48	116.38	-40.87	1.91	20
Price to sales ratio	6.61	5.61	6.22	5.16	5.05
POCF ratio	58.52	42.76	65.68	52.42	36.91
PFCF ratio	107.48	66.72	118.22	100.18	57.48
P/B Ratio	4.4	3.48	4.14	2.36	2.33
PTB ratio	4.4	3.48	4.14	2.36	2.33
EV to sales	10.6	9.78	10.32	8.16	7.92
Enterprise value over EBITDA	111.91	190.9	126.66	-688.07	42.21
EV to operating cash flow	93.81	74.53	108.98	82.95	57.95
EV to free cash flow	172.32	116.28	196.17	158.51	90.24
Earnings yield	0.01	0	-0.01	0.13	0.01
Free cash flow yield	0.01	0.01	0.01	0.01	0.02
Debt to equity	2.95	2.87	3.04	2.09	1.71
Debt to assets	0.61	0.6	0.61	0.55	0.51
Net debt to EBITDA	42.11	81.37	50.33	-253.2	15.32
Current ratio	1.69	1.7	1.42	1.94	1.48
Interest coverage	0.29	-1.13	-0.13	-0.4	2.81
Income quality	2.37	10.64	-1.47	7.16	7.27
Dividend Yield	0.01	0.01	0.01	0.01	0.01
Payout ratio	0.81	3.32	-1.04	0.06	0.6
Sales general and administrative to revenue	0.23	0	0	0	0
Research and developement to revenue	0.04	0.04	0.04	0.04	0.04
Intangibles to total assets	0.48	0.48	0.46	0.41	0.45
Capex to operating cash flow	-0.46	-0.36	-0.44	-0.48	-0.36
Capex to revenue	-0.05	-0.05	-0.04	-0.05	-0.05
Capex to depreciation	-0.6	-0.54	-0.5	-0.56	-0.59
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	9.67	4.78	8.31	42.17	13.42
ROIC	0	0	0	0	0
Return on tangible assets	0.01	0	-0.01	0.14	0.02
Graham Net	-34.23	-34.27	-34.02	-26.39	-25.93
Working capital	3.27B	3.34B	2.44B	5.83B	3.1B
Tangible asset value	-7.74B	-7.57B	-7.26B	-4.47B	-4.13B
Net current asset value	-14.38B	-14.25B	-14.05B	-10.46B	-10.21B
Invested capital	2.95	2.87	3.04	2.09	1.71
Average receivables	2.65B	2.65B	2.52B	2.5B	2.63B
Average payables	1.19B	1.21B	1.27B	1.24B	1.24B
Average inventory	2.7B	2.82B	2.91B	2.89B	2.85B
Days sales outstanding	63.72	62.82	60.57	60.97	63.54
Days payables outstanding	42.29	50.43	42.99	43.28	46.29
Days of inventory on hand	100.92	114.24	100.44	99.8	105.33
Receivables turnover	1.41	1.43	1.49	1.48	1.42
Payables turnover	2.13	1.78	2.09	2.08	1.94
Inventory turnover	0.89	0.79	0.9	0.9	0.85
ROE	0.03	0.01	-0.03	0.31	0.03
Capex per share	-0.4	-0.34	-0.31	-0.34	-0.37

BAX Dividend History

BAX Frequently Asked Questions

What is Baxter International Inc. stock symbol ?

Baxter International Inc. is a US stock , located in Deerfield of Il and trading under the symbol BAX

What is Baxter International Inc. stock quote today ?

Baxter International Inc. stock price is $39.5 today.

Is Baxter International Inc. stock public?

Yes, Baxter International Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 3.62M
Market Capitalization 20.49B
Employee 60K
CEO Mr. Jose E. Almeida
Headquarters Deerfield,IL,US
IPO Date 1981-10-27
Website https://www.baxter.com

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.